IN-VITRO ACTIVITY OF BAY-12-8039, A NEW 8-METHOXYQUINOLONE, COMPARED TO THE ACTIVITIES OF 11 OTHER ORAL ANTIMICROBIAL AGENTS AGAINST 390 AEROBIC AND ANAEROBIC-BACTERIA ISOLATED FROM HUMAN AND ANIMAL BITE WOUNDSKIN AND SOFT-TISSUE INFECTIONS IN HUMANS

The in vitro activity of Bay 12-8039, a new oral 8-methoxyquinolone, w as compared to the activities of 11 other oral antimicrobial agents (c iprofloxacin, levofloxacin, ofloxacin, sparfloxacin, azithromycin, cla rithromycin, amoxicillin clavulanate, penicillin, cefuroxime, cefpodox ime, and doxycycline) against 250 aerobic and 140 anaerobic bacteria r ecently isolated from animal and human bite wound infections, Bay 12-8 039 was active against all aerobic isolates, both gram-positive and gr am-negative isolates, at less than or equal to 1.0 mu g/ml (MICs at wh ich 90% of isolates are inhibited [MIC90s less than or equal to 0.25 m u g/ml) and was active against most anaerobes at less than or equal to 0.5 mu g/ml; the exceptions were Fusobacterium nucleatum and other Fu sobacterium species (MIC(90)s, greater than or equal to 4.0 mu g/ml) a nd one strain of Prevotella loeschii (MICs, 2.0 mu g/ml). In compariso n, the other quinolones tested had similar in vitro activities against the aerobic strains but were less active against the anaerobes, inclu ding peptostreptococci, Porphyromonas species, and Prevotella species. The fusobacteria were relatively resistant to all the antimicrobial a gents tested except penicillin G (one penicillinase-producing strain o ff. nucleatum was found) and amoxicillin clavulanate.